Clinical results of Perftoran application: present and future.
Clinical experience of Perftoran (commercial drug of low concentrated perfluorocheminal emulsion) applications is presented in some statistical data and in brief analysis of clinical trials and following clinical studies described in the Russian scientific literature. Observed data allow us to suppose that Perftoran facilitates oxygen delivery together with remaining red blood cells at blood replacements and will have more wider area for application than just a blood substitute. Its infusion alleviates symptoms of ischemia at different types of occlusion vessels disease, improves grafting in plastic surgery, diminishes inflammation and prevents rejection of transplants, activates detoxication functions of liver, inhibits retro-virus infection development. Local PF applications is able to accelerate wounds and ulcers healing.
Maevsky
Eugene
E
Institute of Theoretical and Experimental Biophysics of RAS, Moscow Region, Russia. emaevsky@iteb.ru
Ivanitsky
Genrih
G
Bogdanova
Ludmila
L
Axenova
Olga
O
Karmen
Natalia
N
Zhiburt
Eugene
E
Senina
Raisa
R
Pushkin
Sergey
S
Maslennikov
Igor
I
Orlov
Andrey
A
Marinicheva
Irina
I
D001802:Blood Substitutes / Q000008:administration & dosage*; D001803:Blood Transfusion / Q000639:trends; D002986:Clinical Trials as Topic; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D010100:Oxygen / Q000378:metabolism*
D001802:Blood Substitutes; D005466:Fluorocarbons; C063334:perftoran; D010100:Oxygen